Boiron SA (ENXTPA: BOI)
Health Care · Pharmaceuticals · FR
€26.00
-0.38% today · +15.5% 1Y
Boiron SA (ENXTPA: BOI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $529.02M and employs 2,499 people.
Over the last twelve months the share price has gained 15.5%, trading between 21.00 and 32.25.
Tweenvest scores Boiron SA across four factors: quality 83/100, value 78/100, growth 2/100, dividend 90/100. Its strongest factor is dividend.
BOI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $529.02M
- Revenue (TTM)
- $588.36M
- P/E
- 13.88
- EPS
- 1.88
- Dividend yield
- 5.19%
- Beta (5Y)
- 0.22
- 52-week high
- €32.25
- 52-week low
- €21.00
- Avg volume (3M)
- —
- Shares outstanding
- 17.36M
- Employees
- 2,499
- Next earnings
- —
About Boiron SA
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-prescription, proprietary, and well-known branded homeopathic treatments. Noteworthy branded offerings include Oscillococcinum, designed to alleviate flu-like symptoms such as fever, chills, headaches, and body aches; Stodal and Stodaline, formulated for cough relief; Arnigel, providing topical support for minor, closed-wound traumas; Camilia, a solution for infant teething discomfort; and Sédatif PC, aimed at managing anxiety, emotional distress, and mild sleep disturbances. Furthermore, its homeopathic range features Coryzalia for addressing cold symptoms and rhinitis; Homéoptic, which targets eye discomfort and irritation in both adults and children; and Homéovox, developed for vocal issues. Beyond its core homeopathic line, Boiron also supplies dietary supplements; Dermoplasmine products (stick, balm, and mousse) for dry skin and lips; Mag' Nuit, an aid for promoting sleep; Arnitrosium for joint pain management; Castor Equi Boiron ointment for cracked skin; and Storinyl syrup for cold symptoms. The company's diverse inventory extends to herbal remedies, exemplified by Canephron, which supports increased urine production and improved urinary tract function; moisturizing lotions for babies; and medical devices, such as COVID-19 self-testing kits and rapid antigen tests. Boiron distributes its extensive product catalog through a comprehensive network encompassing distribution centers, independent pharmacies, pharmacy chains, wholesale partners, grocery and drugstores, specialized health food outlets, and various online retail platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.
- ISIN
- FR0000061129
- Founded
- 1932
- Listed since
- Jan 3, 1991
- Exchange
- Euronext Paris
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.11 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.93 | +0.63% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.78 | +0.15% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.